Open AccessCorrelation of Serum Levels of Interleukine-16, CCL27, Tumor Necrosis Factor-related Apoptosis-inducing Ligand, and B-cell Activating Factor with Multiple Sclerosis Severity
Author(s) -
Ebrahim Kouchaki,
Hossein Akbari,
Fatemeh Tabib Mahmoudi,
Mahdi Salehi,
Effat Naimi,
Hassan Nikoueinejad
Publication year - 2022
Publication title -
iranian journal of allergy, asthma and immunology
Language(s) - English
Resource type - Journals
eISSN - 1735-5249
pISSN - 1735-1502
DOI - 10.18502/ijaai.v21i1.8610
Subject(s) - b cell activating factor , multiple sclerosis , tumor necrosis factor alpha , immunology , pathogenesis , medicine , expanded disability status scale , autoimmune disease , immune system , antibody , b cell
The pathogenic roles of Interleukine-16 (IL-16), CCL27, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), and B-cell activating factor (BAFF) has been shown in some autoimmune and inflammatory diseases. We aimed to correlate the circulatory changes of such factors with the severity of disease in patients with multiple sclerosis (MS).
This case-control study was conducted on 84 MS patients and 83 healthy controls. We measured the serum levels of IL-16, CCL27, TRAIL, and BAFF in all participants by enzyme-linked immune sorbent assay. Using the expanded disability status scale (EDSS), we evaluated the severity of MS. Finally, we assessed the correlation between serum levels of such factors with the severity of MS.
We found increased serum levels of CCL27, IL-16, and BAFF in patients with MS compared to those in healthy subjects. However, no difference was found in serum levels of TRAIL between the patients and controls. In addition, a significant positive correlation between serum levels of CCL27, IL-16, TRAIL, and BAFF with disease severity according to EDSS score was determined.
We showed higher serum levels of CCL27, BAFF, TRAIL, and IL-16 in MS patients with more severe disabilities than mild forms. Such finding may represent their contribution to the pathogenesis of MS. Blocking such molecules may yield new treatments for MS.